ArticleJournal of the American Heart Association2026
Statin Use and Recurrent Atherosclerotic Cardiovascular Disease Events in Patients With Coronary Artery Intervention: A Retrospective Analysis From a Large Health Care Network.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerotic cardiovascular disease (ASCVD) poses a significant health challenge worldwide. While statins effectively reduce low-density lipoprotein (LDL) cholesterol and lower cardiovascular risk, patients with coronary artery disease who undergo revascularization remain vulnerable to recurrent ASCVD events. This study examined the link between statin intensity, LDL cholesterol levels, and recurrent ASCVD events in patients undergoing coronary interventions within a large health care system.
methodsWe conducted a retrospective analysis using the University of Pittsburgh Medical Center database, including patients aged ≥18 with coronary artery disease confirmed by revascularization (coronary artery bypass graft or percutaneous coronary intervention) since January 2010. Patients were categorized by statin intensity: guideline-directed statin intensity (GDSI), less than GDSI (<GDSI), or no statin therapy. Outcomes included recurrent myocardial infarction, ischemic stroke, and all-cause mortality over a median 6-year follow-up.
resultsOf 45 949 patients (69% men), 65% were on GDSI, 25% on <GDSI, and 10% were not on statins. GDSI patients compared with those on <GDSI or no statins had lower rates of myocardial infarction (21.6 versus 34.8 versus 65.3), myocardial infarction/revascularization (38.7 versus 57.5 versus 93.9), and ischemic stroke/transient ischemic attack (10.7 versus 17.7 versus 24.6) (
conclusionsGDSI reduces recurrent ASCVD events and mortality more effectively than less intensive regimens or no statins. Optimizing statin use and LDL cholesterol monitoring could improve ASCVD management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.